Centocor sees growing demand for Remicade
Executive Summary
The Crohn's disease therapy Remicade (infliximab) posted $21.1 mil. in sales for the first quarter, compared to $23.9 mil. in the fourth quarter immediately following launch, Centocor said. "First quarter sales reflected the fact that pent-up demand for Remicade was largely satisfied in the fourth quarter," the firm said. "Demand for the drug is growing, reflecting the high level of physician and patient satisfaction we have seen since the drug became commercially available"
You may also be interested in...
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Shire Hopes To Sow Future Deals With $50M Venture Fund
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth